February 14, 2017 / 9:28 PM / 7 months ago

BRIEF-Neurocrine Biosciences reports Q4 loss per share $0.51

Feb 14 (Reuters) - Neurocrine Biosciences Inc

* Neurocrine Biosciences reports year-end 2016 results and provides investor update for 2017

* Q4 loss per share $0.51

* Q4 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S

* Neurocrine Biosciences Inc- Revenues from milestones under abbvie agreement for 2017 are expected to be $30 million

* Neurocrine Biosciences-2017 ongoing operating expenses should approximate $230 million to $240 million, exclusive of $30 million up-front fee for in-licensing opicapone Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below